Grow each trial patient's tumour as organoids to decide which platform arm opens next
While patients are treated in a platform trial, their tumour cells grow in a dish and are tested against dozens of drug pairs. The pairs that win in the dish become the next arms.
Co-clinical organoid programmes (for example in pancreatic and colorectal cancer) have tested whether dish responses predict patient responses. The proposal inverts the use: a platform trial's organoid bank becomes a combination discovery engine, testing hundreds of pairs on the same tumours that are being treated, so the next arm is chosen from data on the trial population itself rather than on generic cell lines.
- Too many combinations to test · There are thousands of possible drug pairs and sequences. Trials can test a few dozen a year.
- Preclinical models that do not predict people · Nine in ten cancer drugs that work in mice fail in humans. Our models are the reason.
Pages like this
not linked directly; found by shared links- TechnologyOrganoid-guided therapy at scale
Shares Curesponse, PDAC organoid pharmacotyping, SEngine Precision Medicine, Xilis.
- IdeaHold organoid drug tests to the same standard as a diagnostic test
Shares Curesponse, SEngine Precision Medicine, Xilis, Functional (ex vivo) drug testing.
- IdeaTest drugs on the patient's own cancer cells when there is no trial to join
Shares Curesponse, SEngine Precision Medicine, Xilis, Functional (ex vivo) drug testing.
- IdeaAutomated combination discovery: patient-sample screens feeding Bayesian platform trials
Shares Patient-derived organoids to pick ADC payloads, Functional (ex vivo) drug testing, Patient-derived organoids, Too many combinations to test.
- IdeaRun the mouse or organoid trial at the same time as the human trial
Shares Xilis, Patient-derived organoids to pick ADC payloads, Functional (ex vivo) drug testing, Patient-derived organoids.
- IdeaTest drugs on freshly cut slices of the patient's own tumour
Shares Curesponse, Functional (ex vivo) drug testing, Patient-derived organoids, Preclinical models that do not predict people.
- PersonDavid A. Tuveson
Shares PDAC organoid pharmacotyping, Functional (ex vivo) drug testing, Patient-derived organoids, Pancreatic ductal adenocarcinoma.
- IdeaZebrafish avatars for a drug answer within a week
Shares Functional (ex vivo) drug testing, Preclinical models that do not predict people, Pancreatic ductal adenocarcinoma, Colorectal cancer.